Altered Morphine Glucuronide and Bile Acid Disposition in Patients With Nonalcoholic Steatohepatitis

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 4, 2015, Pages 419-427

  Ferslew, B C ^a   Johnston, C K ^a   Tsakalozou, E ^a   Bridges, A S ^b   Paine, M F ^a   Jia, W ^c   Stewart, P W ^d   Barritt, A S ^b   Brouwer, K L R ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; MORPHINE DERIVATIVE; MORPHINE-3-GLUCURONIDE; MORPHINE-6-GLUCURONIDE; NARCOTIC ANALGESIC AGENT;

ADULT; AREA UNDER THE CURVE; COHORT ANALYSIS; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; BILE ACIDS AND SALTS; COHORT STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORPHINE DERIVATIVES; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84929138347     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/CPT.66     Document Type: Article

References (48)

1. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592–1609 (2012).
2. Browning, J.D. et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387– 1395 (2004).
3. Williams, C.D. et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124–131 (2011).
4. Torres, D.M., Jones, F.J., Shaw, J.C., Williams, C.D., Ward, J.A. & Harrison, S.A. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, openlabel trial. Hepatology 54, 1631–1639 (2011).
5. Tikkanen, M.J. et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int. J. Cardiol. 168, 3846–3852 (2013).
6. Sanyal, A.J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–85 (2010).
7. Nakahara, T. et al. Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol. Res. 42, 1065–72 (2012).
8. Chu, X. et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin. Pharmacol. Ther. 94, 126–41 (2013).
9. Kock, K. & Brouwer, K.L.R. A perspective on efflux transport proteins in the liver. Clin. Pharmacol. Ther. 92, 599–612 (2012).
10. Zamek-Gliszczynski, M.J., Chu, X., Polli, J.W., Paine, M.F. & Galetin, A. Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metab. Disp. 42, 650–664 (2014).
11. Pfeifer, N.D. et al. Effect of ritonavir on (99m) technetium-mebrofenin disposition in humans: a semi-PBPK modeling and in vitro approach to predict transporter-mediated DDIs. CPT Pharmacometrics Syst. Pharmacol. 2, e20 (2013).
12. Filppula, A.M., Tornio, A., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8mediated formation of its main metabolite. Clin. Pharmacol. Ther. 94, 383–393 (2013).
13. Jonker, J.W., Liddle, C. & Downes, M. FXR and PXR: potential therapeutic targets in cholestasis. J. Steroid Biochem. Mol. Biol. 130, 147–158 (2012).
14. Fisher, C.D. et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Disp. 37, 2087–2094 (2009).
15. Hardwick, R.N., Fisher, C.D., Canet, M.J., Scheffer, G.L. & Cherrington, N.J. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Disp. 39, 2395–2402 (2011).
16. Hardwick, R.N. et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Disp. 41, 554– 561 (2013).
17. Lake, A.D. et al. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Disp. 39, 1954–1960 (2011).
18. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652–662 (2009).
19. Pfeifer, N.D., Hardwick, R.N. & Brouwer, K.L.R. Role of hepatic efflux transporters in regulating systemic and hepatocyte exposure to xenobiotics. Annu. Rev. Pharmacol. Toxicol. 54, 509–535 (2014).
20. Tzvetkov, M.V., dos Santos Pereira, J.N., Meineke, I., Saadatmand, A.R., Stingl, J.C. & Brockmoller, J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem. Pharmacol. 86, 666–678 (2013).
21. Bodenham, A., Quinn, K. & Park, G.R. Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation. Br. J. Anaesth. 63, 380–384 (1989).
22. Zelcer, N. et al. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci. U S A 102, 7274–7279 (2005).
23. van de Wetering, K. et al. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol. Pharmacol. 72, 387–394 (2007).
24. Holthe, M. et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58, 353–356 (2002).
25. Xiong,H.,Suzuki,H.,Sugiyama,Y.,Meier,P.J.,Pollack,G.M.& Brouwer, K.L.R. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab. Disp. 30, 962–969 (2002).
26. Yamaguchi, K., Murai, T., Yabuuchi, H. & Kurosawa, T. Measurement of transport activities of bile acids in human multidrug resistanceassociated protein 3 using liquid chromatography-tandem mass spectrometry. Anal. Sci. 26, 317–323 (2010).
27. Ahlberg, J., Angelin, B., Bjorkhem, I. & Einarsson, K. Individual bile acids in portal venous and systemic blood serum of fasting man. Gastroenterology 73, 1377–1382 (1977).
28. Osborne, R., Joel, S., Trew, D. & Slevin, M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6glucuronide. Clin. Pharmacol. Ther. 47, 12–19 (1990).
29. Everts, B., Karlson, B.W., Herlitz, J. & Hedner, T. Morphine use and pharmacokinetics in patients with chest pain due to suspected or definite acute myocardial infarction. Eur. J. Pain 2, 115–125 (1998).
30. Garcia-Canaveras, J.C., Donato, M.T., Castell, J.V. & Lahoz, A. Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. J. Lipid Res. 53, 2231–2241 (2012).
31. Johnston, C.K., Ferslew, B.C., Barritt, A.S. & Brouwer, K.L.R. Mathematical modeling of systemic and hepatic disposition of morphine and morphine glucuronides in nonalcoholic steatohepatitis to inform study design. Poster presentation at the 2013 AAPS Annual Meeting and Exposition; November 10–14, 2013; San Antonio, TX. Poster T3196.
32. Imajo, K. et al. Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J. Gastroenterol. 49, 295–304 (2014).
33. Lockman, P. & Allen, D. The transport of choline. Drug Dev. Indust. Pharm. 28, 749–771 (2002).
34. Clarke, J.D., Hardwick, R.N., Lake, A.D., Canet, M.J. & Cherrington, N.J. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression. J. Pharmacol. Exp. Ther. 348, 452– 458 (2014).
35. Yamazaki, M. et al. Perturbation of bile acid homeostasis is an early pathogenesis event of drug induced liver injury in rats. Toxicol. Appl. Pharmacol. 268, 79–89 (2013).
36. Pou, L. et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther. Drug Monitor. 23, 35–38 (2001).
37. Matsunaga, N., Wada, S., Nakanishi, T., Ikenaga, M., Ogawa, M. & Tamai, I. Mathematical modeling of the in vitro hepatic disposition of mycophenolic acid and its glucuronide in sandwich-cultured human hepatocytes. Mol. Pharm. 11, 568–579 (2014).
38. Pfeifer, N.D., Bridges, A.S., Ferslew, B.C., Hardwick, R.N. & Brouwer, K.L.R. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J. Pharmacol. Exp. Ther. 347, 737–745 (2013).
39. Pfeifer, N.D., Yang, K. & Brouwer, K.L.R. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition: characterization of basolateral vs. biliary clearance using a novel protocol in sandwichcultured hepatocytes. J. Pharmacol. Exp. Ther. 347, 727–736 (2013).
40. Lake, A.D. et al. Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease. Toxicol. Appl. Pharmacol. 268, 132–140 (2013).
41. Kleiner, D.E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
42. Clavijo, C.F. et al. A sensitive assay for the quantification of morphine and its active metabolites in human plasma and dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 400, 715–728 (2011).
43. Chen, S. Physiologically based pharmacokinetic (PBPK) models for the description of sequential metabolism of codeine to morphine and morphine 3-glucuronide (M3G) in man and rat. Thesis, University of Toronto (2010).
44. Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R. & Beliles, R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Indust. Health 13, 407–484 (1997).
45. Hanna, M.H., Peat, S.J., Knibb, A.A. & Fung, C. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br. J. Anaesth. 66, 103–107 (1991).
46. Lotsch, J., Skarke, C., Schmidt, H., Liefhold, J. & Geisslinger, G. Pharmacokinetic modeling to predict morphine and morphine-6glucuronide plasma concentrations in healthy young volunteers. Clin. Pharmacol. Ther. 72, 151–162 (2002).
47. Skarke, C., Schmidt, H., Geisslinger, G., Darimont, J. & Lotsch, J. Pharmacokinetics of morphine are not altered in subjects with Gilbert’s syndrome. Br. J. Pharmacol. 56, 228–231 (2003).
48. Murthy, B.R., Pollack, G.M. & Brouwer, K.L.R. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J. Clin. Pharmacol. 42, 569–576 (2002).